Chrys Kokino is President of U.S. BioPharma at Accord BioPharma. With over 31 years of experience, spanning multiple therapeutic areas such as oncology, immunology, and endocrinology, he has held senior leadership roles at top-tier pharma and biotech companies such as BMS, Amgen, Roche. Chrys had the good fortune of launching some of the world’s first biosimilars when he represented Sandoz and Mylan. Now, in his current role as President of Accord BioPharma, the organization has a singular focus of launching biosimilars, specialty products, and complex molecules in the U.S. to provide value to the U.S. market, value to U.S. stakeholders, and most importantly, value to U.S. patients by providing cost effective treatment options to some of the currently available cost prohibitive medicines.